Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | DRD3 | P35462 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14876092 | 0.84 | EGLN1 (0.57) | EGLN1HDAC3HDAC1EGFRHDAC2 | |
| SCHEMBL14875993 | 0.83 | EGLN1 (0.57) | EGLN1MAPTALDH1A1HDAC3HDAC1 | |
| SCHEMBL5160768 | 0.83 | EGLN1 (0.50) | EGLN1MAPTGAAALDH1A1HDAC3 | |
| SCHEMBL14883271 | 0.82 | EGLN1 (0.56) | EGLN1MAPTALDH1A1HDAC3HDAC1 | |
| SCHEMBL14885756 | 0.81 | EGLN1 (0.56) | EGLN1HDAC3HDAC1EGFRHDAC2 | |
| SCHEMBL4078388 | 0.81 | KDM4E (0.56) | EGLN1MAPTALDH1A1HDAC3HDAC1 | |
| SCHEMBL16307678 | 0.81 | HDAC3 (0.57) | EGLN1HDAC3HDAC1EGFRHDAC2 | |
| SCHEMBL5100085 | 0.81 | EGLN1 (0.52) | EGLN1ALDH1A1HDAC3HDAC1EGFR | |
| SCHEMBL1208104 | 0.80 | EGLN1 (0.62) | EGLN1HDAC3HDAC1EGFRHDAC2 | |
| SCHEMBL209902 | 0.80 | ABL1 (0.44) | EGLN1MAPTGAAALDH1A1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117736142-A | Isoquinoline-3-acylhydrazone disulfone compound and preparation method and application thereof | 江西科技师范大学 | 2024-03-22 | — | — | CN | claimed |
| CN-114478382-A | Isoquinoline-3-hydrazide compound and preparation method and application thereof | 贵州大学 | 2022-05-13 | — | — | CN | claimed |
| CN-119504582-A | Isoquinoline-3-acylhydrazone aromatic ring cycloalkane compound and application thereof in plant disease control | 中国热带农业科学院环境与植物保护研究所 | 2025-02-25 | — | — | CN | disclosed |
| CN-117736142-A | Isoquinoline-3-acylhydrazone disulfone compound and preparation method and application thereof | 江西科技师范大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-114478382-A | Isoquinoline-3-hydrazide compound and preparation method and application thereof | 贵州大学 | 2022-05-13 | — | — | CN | disclosed |
| CN-114478382-A | Isoquinoline-3-hydrazide compound and preparation method and application thereof | 贵州大学 | 2022-05-13 | — | — | CN | disclosed |
| CN-114478382-A | Isoquinoline-3-hydrazide compound and preparation method and application thereof | 贵州大学 | 2022-05-13 | — | — | CN | disclosed |
| US-20200125564-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2020-04-23 | — | — | US | disclosed |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2020-01-28 | — | — | US | disclosed |
| US-10065960-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2018-09-04 | — | — | US | disclosed |
| US-20180194772-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2018-07-12 | — | — | US | disclosed |
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011121137-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | EUROSCREEN S.A. (BE) | 2011-10-06 | — | — | WO | disclosed |
| EP-2371219-A1 | Herbicidal acylhydrazides | BASF SE (DE) | 2011-10-05 | — | — | EP | disclosed |
| EP-2195328-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Incorporated (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
| WO-2009023193-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023193-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | EGLN1 4270/4885MAPT 530/4885GAA 346/4885 |
| US-10065960-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | BDKRB2, ACKR3, KLRK1 | EGLN1 4436/4885MAPT 4528/4885GAA 1199/4885 |
| US-20180194772-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | EGLN1 4185/4885MAPT 4547/4885GAA 1377/4885 |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | BDKRB2, ACKR3, KLRK1 | EGLN1 4436/4885MAPT 4528/4885GAA 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.